dual gip and glp-1 receptor agonist Main physiological actions of the Potential Use of GLP-1 and
Description
Diagnostics (Basel) 2024;14:2829.ArticlePubMedPMC 7

[DOI] [PubMed] [Google Scholar] 42.Schmitt C, Portron A, Jadidi S, Sarkar N & DiMarchi R Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus

1.1 per 1,000 person-years

Three diabetes incretin medications are now approved for pediatric use starting at age 10 (see cheat sheet), and two incretin-based weight management medications are approved for children aged 12 and older

Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period
Pharmacol Rep
